Spectrum Pharmaceuticals, Inc. Business Operations Contracts & Agreements
28 Contracts & Agreements
- Development Agreements (3 contracts)
- Indemnification Agreements (1)
- Sales Agreements (14)
- Supply Agreements (9)
- Voting Agreements (1)
- Second Amendment to Supply Agreement, dated as of January 1, 2022, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd (Filed With SEC on March 31, 2023)
- First Amendment to Supply Agreement, dated as of December 6, 2019, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd (Filed With SEC on March 31, 2023)
- Supply Agreement, dated as of February 28, 2018, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd (Filed With SEC on March 31, 2023)
- Form of Indemnification Agreement of Spectrum Pharmaceuticals, Inc (Filed With SEC on March 2, 2020)
- SPECTRUM PHARMACEUTICALS CAYMAN, L.P. and MUNDIPHARMA MEDICAL COMPANY SUPPLY AGREEMENT (Filed With SEC on March 14, 2016)
- ALLOS THERAPEUTICS, INC. and MUNDIPHARMA MEDICAL COMPANY AMENDED AND RESTATED SUPPLY AGREEMENT TABLE OF CONTENTS (Filed With SEC on August 9, 2013)
- SUPPLY AGREEMENT (Filed With SEC on May 9, 2013)
- MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on November 9, 2012)
- CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO... (Filed With SEC on November 9, 2012)
- TENDER AND VOTING AGREEMENT (Filed With SEC on April 5, 2012)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on March 10, 2011)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on April 5, 2010)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on April 5, 2010)
- Maximizing the growth potential of our marketed drugs, Zevalin and Fusilev. Our near-term outlook largely depends on sales and marketing successes for our two marketed drugs. For... (Filed With SEC on April 5, 2010)
- Maximizing the growth potential for our marketed drugs, Fusilev and Zevalin. The companys near-term outlook depends on sales and marketing successes associated with our two... (Filed With SEC on March 31, 2009)
- Maximizing the growth potential for our marketed drugs, Fusilev and Zevalin. The companys near-term outlook depends on sales and marketing successes associated with our two... (Filed With SEC on March 31, 2009)
- MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on August 8, 2006)
- Eight proprietary drug product candidates, or drug products with respect to which we have patent rights, either directly or through licensing, under development, including one in... (Filed With SEC on March 15, 2006)
- Eight proprietary drug product candidates, or drug products with respect to which we have patent rights, either directly or through licensing, under development, including one in... (Filed With SEC on March 15, 2006)
- Eight proprietary drug product candidates, or drug products with respect to which we have patent rights, either directly or through licensing, under development, including one in... (Filed With SEC on March 15, 2006)
- Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co (Filed With SEC on October 24, 2001)
- Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co (Filed With SEC on October 24, 2001)
- Amendment to Sales Agreement, dated as of October 19, 2001, by and between Registrant and Cantor Fitzgerald & Co (Filed With SEC on October 24, 2001)
